Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of 2410.HK is 24 and suggests 89% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell